3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
105
Carcinoma, Hepatocellular
34
Gastrointestinal Stromal Tumors
17
Colonic Neoplasms
14
Rectal Neoplasms
12
Neoplasm Metastasis
12
Liver Neoplasms
8
Stomach Neoplasms
5
Cholangiocarcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Sarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Colorectal Cancer Metastatic
3
Carcinoma, Renal Cell
3
Advanced Colorectal Cancer
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Lung Neoplasms
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Cancer Liver Metastases
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
pembrolizumab
4
Nivolumab
3
sintilimab
2
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
Bevacizumab
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
relatlimab
1
regorafenib
1
epacadostat
1
dabrafenib
1
copanlisib
1
binimetinib
1
atezolizumab
1
Tiragolumab
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Fulvestrant
1
E7046
1
Cetuximab
1
Capecitabine
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
regorafenib
×
Gastrointestinal
×
Clear all
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled